EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

A. J. Rabelink; D. W. Erkelens; R. J. Hené; J. A. Joles; H. A. Koomans

doi:10.1016/S0140-6736(88)90870-7

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

A. J. Rabelink^*, D. W. Erkelens, R. J. Hené, J. A. Joles, H. A. Koomans

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

86 Citations (Scopus)

Abstract

The efficacy, safety, and tolerability of simvastatin (20 mg twice a day) in the treatment of hyperlipidaemia due to unremitting nephrotic syndrome was compared with that of cholestyramine (8 g twice a day) in a crossover trial in ten patients. Two patients were taken off the protocol, one because he could not tolerate cholestyramine and one because of non-compliance with the cholestyramine regimen. No clinical or laboratory adverse experiences were noticed during the study in the other eight patients. Simvastatin was significantly more effective than cholestyramine in reducing the hyperlipidaemia-it produced a 36% decrease in total cholesterol and a 39% decrease in low density (LDL)-cholesterol, whereas cholestyramine reduced total cholesterol by 8% and LDL-cholesterol by 19%. With simvastatin the apolipoprotein B level decreased by 30%, whereas the apolipoprotein A level increased by 10%.

Original language	English
Pages (from-to)	1335-1338
Number of pages	4
Journal	The Lancet
Volume	332
Issue number	8624
DOIs	https://doi.org/10.1016/S0140-6736(88)90870-7
Publication status	Published - 10 Dec 1988

Access to Document

10.1016/S0140-6736(88)90870-7

Cite this

@article{501435d33cb14979abc88f5f19984b29,

title = "EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME",

abstract = "The efficacy, safety, and tolerability of simvastatin (20 mg twice a day) in the treatment of hyperlipidaemia due to unremitting nephrotic syndrome was compared with that of cholestyramine (8 g twice a day) in a crossover trial in ten patients. Two patients were taken off the protocol, one because he could not tolerate cholestyramine and one because of non-compliance with the cholestyramine regimen. No clinical or laboratory adverse experiences were noticed during the study in the other eight patients. Simvastatin was significantly more effective than cholestyramine in reducing the hyperlipidaemia-it produced a 36% decrease in total cholesterol and a 39% decrease in low density (LDL)-cholesterol, whereas cholestyramine reduced total cholesterol by 8% and LDL-cholesterol by 19%. With simvastatin the apolipoprotein B level decreased by 30%, whereas the apolipoprotein A level increased by 10%.",

author = "Rabelink, {A. J.} and Erkelens, {D. W.} and Hen{\'e}, {R. J.} and Joles, {J. A.} and Koomans, {H. A.}",

year = "1988",

month = dec,

day = "10",

doi = "10.1016/S0140-6736(88)90870-7",

language = "English",

volume = "332",

pages = "1335--1338",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8624",

}

TY - JOUR

T1 - EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

AU - Rabelink, A. J.

AU - Erkelens, D. W.

AU - Hené, R. J.

AU - Joles, J. A.

AU - Koomans, H. A.

PY - 1988/12/10

Y1 - 1988/12/10

N2 - The efficacy, safety, and tolerability of simvastatin (20 mg twice a day) in the treatment of hyperlipidaemia due to unremitting nephrotic syndrome was compared with that of cholestyramine (8 g twice a day) in a crossover trial in ten patients. Two patients were taken off the protocol, one because he could not tolerate cholestyramine and one because of non-compliance with the cholestyramine regimen. No clinical or laboratory adverse experiences were noticed during the study in the other eight patients. Simvastatin was significantly more effective than cholestyramine in reducing the hyperlipidaemia-it produced a 36% decrease in total cholesterol and a 39% decrease in low density (LDL)-cholesterol, whereas cholestyramine reduced total cholesterol by 8% and LDL-cholesterol by 19%. With simvastatin the apolipoprotein B level decreased by 30%, whereas the apolipoprotein A level increased by 10%.

AB - The efficacy, safety, and tolerability of simvastatin (20 mg twice a day) in the treatment of hyperlipidaemia due to unremitting nephrotic syndrome was compared with that of cholestyramine (8 g twice a day) in a crossover trial in ten patients. Two patients were taken off the protocol, one because he could not tolerate cholestyramine and one because of non-compliance with the cholestyramine regimen. No clinical or laboratory adverse experiences were noticed during the study in the other eight patients. Simvastatin was significantly more effective than cholestyramine in reducing the hyperlipidaemia-it produced a 36% decrease in total cholesterol and a 39% decrease in low density (LDL)-cholesterol, whereas cholestyramine reduced total cholesterol by 8% and LDL-cholesterol by 19%. With simvastatin the apolipoprotein B level decreased by 30%, whereas the apolipoprotein A level increased by 10%.

UR - http://www.scopus.com/inward/record.url?scp=0024227363&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(88)90870-7

DO - 10.1016/S0140-6736(88)90870-7

M3 - Article

C2 - 2904053

AN - SCOPUS:0024227363

SN - 0140-6736

VL - 332

SP - 1335

EP - 1338

JO - The Lancet

JF - The Lancet

IS - 8624

ER -

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

Abstract

Access to Document

Other files and links

Fingerprint

Cite this